GRTS - Gritstone bio, Inc.
After hours:
| Previous Close | 2.3800 |
| Open | 2.4100 |
| Bid | 0.0000 x 2200 |
| Ask | 0.0000 x 1300 |
| Day's Range | 2.2700 - 2.4400 |
| 52 Week Range | 1.6400 - 5.8500 |
| Volume | |
| Avg. Volume | 637,985 |
| Market Cap | 212.504M |
| Beta (5Y Monthly) | 0.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5300 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.60 |
GlobeNewswireGritstone bio to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor conferences: Goldman Sachs 44th Annual Healthcare Conference (Fireside Chat)Fireside Chat Date and Time: Monday, June 12 at 4:00pm PTSpeaker: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive OfficerLocation: Dana Point
- GlobeNewswire
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 31,000 shares of its common stock with an exercise price of $1.96, which is equal to the closing price of Gritstone’s common stock on May 16, 2023, the date
Simply Wall St.The Consensus EPS Estimates For Gritstone bio, Inc. (NASDAQ:GRTS) Just Fell Dramatically
The latest analyst coverage could presage a bad day for Gritstone bio, Inc. ( NASDAQ:GRTS ), with the analysts making...
- GlobeNewswire
Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates
-- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE (personalized vaccine in first-line metastatic microsatellite-stable colorectal cancer [MSS-CRC]) to date; 71 of 80 patients (initial target) enrolled as of May 10, 2023 -- -- Gritstone prioritizing GRANITE; expanding Phase 2 from 80 to 100 patients, enrollment completion expected in 3Q2023, preliminary data on approximately 50 patients expected in 1Q2024 -- -- Cash, cash equivalents, marketable securities, and rest
- GlobeNewswire
Gritstone bio to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 11, 2023
-- Conference call to begin at 4:30pm ET on May 11 --EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report its first quarter 2023 financial results and provide a corporate update following market close on Thursday, May 11, 2023. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET. Live Con
- Simply Wall St.
Both individual investors who control a good portion of Gritstone bio, Inc. (NASDAQ:GRTS) along with institutions must be dismayed after last week's 14% decrease
Key Insights Gritstone bio's significant individual investors ownership suggests that the key decisions are influenced...
- GlobeNewswire
Gritstone bio Presents 6-month Neutralizing Antibody (nAb) Data at ECCMID 2023 from Two Phase 1 Studies Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 (CORAL)
-- CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody (nAb) responses that persist for at least 6 months, including variant cross-reactive nAb, in previously unvaccinated (“vaccine-naïve”) South African subjects -- -- Updated CORAL-BOOST: Boost samRNA vaccine elicits robust nAbs that persist for at least 6 months regardless of primary series (adenovirus or mRNA) -- -- Data further support the favorable tolerability and distinctive immunogenicity profile of self-am
- GlobeNewswire
Gritstone bio Presents Advances in Neoantigen Prediction and Cancer Vaccine Immunogenicity at the 2023 AACR Annual Meeting
-- Longitudinal analysis of GRANITE recipients (personalized vaccine candidate now in Phase 2/3 for MSS-CRC) demonstrates vaccine-elicited priming and boosting of antigen-specific T cell populations associated with conversion of “cold” to “hot” tumors and molecular responses -- -- Advances in EDGE™ models (Gritstone’s AI-driven neoantigen prediction platform) enable best-in-class prediction of class II HLA-presented neoantigens that could drive CD4+ T cell responses -- -- A novel KRAS G12C class
- GlobeNewswire
Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023
EMERYVILLE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced multiple presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023), taking place April 15-18, 2023 in Copenhagen, Denmark. Both presentations are from the company’s CORAL program, which is evaluating various self-amplifying mRNA (samRNA) vaccine candid
- GlobeNewswire
Gritstone bio Announces Presentations on Neoantigen Prediction Capabilities and Cancer Vaccine Programs at the 2023 AACR Annual Meeting
EMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced multiple presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023 in Orlando, Florida. The poster presentations will address the company’s proprietary neoantigen prediction capabilities (EDGE™) and “off-the-shelf" neoantigen vaccine prog
- Simply Wall St.
Gritstone bio Full Year 2022 Earnings: Beats Expectations
Gritstone bio ( NASDAQ:GRTS ) Full Year 2022 Results Key Financial Results Revenue: US$19.9m (down 59% from FY 2021...
- GlobeNewswire
Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
-- Preliminary data from GRANITE Phase 2/3 study (individualized vaccine for first-line microsatellite-stable colorectal cancer [MSS-CRC]) remain expected in 4Q 2023 -- -- Phase 1/2 efficacy signals from “off-the-shelf” vaccine program (SLATE) consistent with those from GRANITE; randomized study of SLATE in patients with newly-diagnosed metastatic cancer to initiate in 2H 2023 -- -- Clinical evidence building for differentiation of self-amplifying mRNA (samRNA) as a potential next-gen mRNA platf
- GlobeNewswire
Gritstone bio to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 9, 2023
Conference call to begin at 4:30pm ET on March 9EMERYVILLE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report its fourth quarter and full year 2022 financial results and provide a corporate update following market close on Thursday, March 9, 2023. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm
GlobeNewswireGritstone bio to Participate in 43rd Annual Cowen Healthcare Conference
EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Gritstone’s Co-founder, President and Chief Executive Officer will participate in the “Novel Immuno-Oncology” panel at the Cowen 43rd Annual Healthcare Conference on March 6, 2023. Panel DetailsTitle: Novel I-O Corporate PanelDate and Time: Monday, March 6, 2023 from 9:
- GlobeNewswire
Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination
-- NCI will lead the Phase 1 study using Gritstone’s proprietary “off the shelf” vaccine technology for mutant KRAS solid tumors --EMERYVILLE, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it has entered into a clinical trial agreement with the National Cancer Institute (NCI), an institute of the National Institutes of Health, to evaluate an autologous
- Simply Wall St.
Investors in Gritstone bio (NASDAQ:GRTS) have unfortunately lost 66% over the last three years
It is doubtless a positive to see that the Gritstone bio, Inc. ( NASDAQ:GRTS ) share price has gained some 32% in the...
- GlobeNewswire
Gritstone bio to Present at 41st Annual J.P. Morgan Healthcare Conference
EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference occurring January 9-12, 2023 in San Francisco. The presentation will take place on Thursday, January 12, 2023 from 9:45 - 10:25 AM Pacific Time in Elizab
- GlobeNewswire
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted five employees nonqualified stock options to purchase an aggregate of 46,950 shares of its common stock with an exercise price of $2.69, which is equal to the closing price of Gritstone’s common stock on December 6, 2022, the date of the grant. These sto
- GlobeNewswire
Gritstone bio Granted Two New U.S. Patents for Self-amplifying mRNA (samRNA)
-- Patents support Gritstone’s pioneering work in the application of next-generation samRNA vaccine technology in oncology and infectious disease --EMERYVILLE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that the United States Patent and Trademark Office (USPTO) recently issued two new patents related to the company’s novel self-amplifying mRNA (samRNA) va
GlobeNewswirePredictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D. to the Board of Directors
Matthew Hawryluk, Ph.D. POAI Board of Directors EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board of Directors to help support the company’s strategic initiatives and commercialization efforts. Dr. Hawryluk currently serves as Executive Vice President and Chief Business Officer of Gritstone bio, Inc (Nasdaq: GRTS). Recognized by Pharmaceutical Exe
- GlobeNewswire
Gritstone to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that Gritstone management will participate in the following upcoming investor conferences. 5th Annual Evercore ISI HealthCONx ConferenceFireside Chat Date and Time: Tuesday, November 29, 2022 at 10:30am ESTPresenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive OfficerLocati
- GlobeNewswire
Gritstone Announces Updated Overall Survival Results from GRANITE Phase 1/2 Study and Poster at SITC 2022
-- Median overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy and had molecular response will now exceed 22 months – median not yet reached -- -- Patients who achieve a molecular response include those with liver metastasis and are not enriched for baseline PD-L1 expression, high tumor mutation burden or IFNg-related genes -- EMERYVILLE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS
- GlobeNewswire
Gritstone Reports Third Quarter 2022 Financial Results and Provides Business Update
-- Two Phase 1 CORAL (SARS-CoV-2) studies deliver positive results, provide further proof-of-concept for application of self-amplifying mRNA (samRNA) as infectious disease vaccine platform -- -- Initial Phase 2 data from KRAS-directed SLATE ("off-the-shelf" neoantigen program) show similar signals in non-small cell lung cancer (NSCLC) as GRANITE (individualized neoantigen program) in colorectal cancer (CRC) -- -- GRANITE randomized Phase 2/3 study in 1L metastatic CRC with registrational intent
- GlobeNewswire
Gritstone bio Announces Private Placement of $45.0 Million
EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that it has executed a securities purchase agreement to sell, through a private investment in public equity (PIPE) financing, 6,637,165 shares of its common stock at a price of $2.26 per share of common stock and 13,274,923 pre-funded warrants to purchase up to 13,274,923 shares of common stock at a
- GlobeNewswire
Gritstone Presents Positive Results from Two Phase 1 CORAL Studies, Providing Further Proof-of-Concept for Self-amplifying mRNA (samRNA) in Infectious Diseases
-- New data from CORAL-BOOST study demonstrate broad and durable immune response; high neutralizing antibody and T cell responses at 6 months post-boost vaccination -- -- Interim results from CORAL-CEPI show good tolerability and immunogenicity in all vaccine-naïve subjects dosed -- -- Data provide further support of Gritstone’s self-amplifying mRNA (samRNA) as platform for infectious disease vaccines -- EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a